Trials / Completed
CompletedNCT06315634
Intrathecal Dexmedetomidine vs Midazolame
Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- National Cancer Institute, Egypt · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries
Detailed description
Comparison of intrathecal dexmedetomidine plus Bupivacaine vs intrathecal midazolam plus Bupivacaine on duration of sensory and motor blockade and hemodynamic parameters of patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine | 5 micrograms intrathecal dexmedetomidine |
| DRUG | Midazolam | 2 milligrams intrathecal midazolam |
| DRUG | Bupivacain | 12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine |
Timeline
- Start date
- 2021-03-15
- Primary completion
- 2022-03-10
- Completion
- 2022-03-10
- First posted
- 2024-03-18
- Last updated
- 2024-03-18
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06315634. Inclusion in this directory is not an endorsement.